The acronym most pharma teams use without defining GxP stands for “Good x Practice,” where x is a placeholder for the specific domain of pharmaceutical regulation: manufacturing (GMP), laboratory (GLP), clinical (GCP), distribution (GDP), and pharmacovigilance (GVP). Each domain has its own regulatory guidance, enforcement body, and documentation requirements. Together, they form the framework ensuring that pharmaceutical products are consistently produced, tested, distributed, and monitored to quality standards appropriate for their intended use. For engineering and IT teams, the practical consequence is that any system touching GxP-relevant data — batch records, test results, environmental monitoring, adverse event reports — must meet specific requirements for validation, audit trails, electronic signatures, and change control. Systems outside that scope do not carry these obligations, regardless of where they physically sit in the facility. The hard work is not memorising the acronyms; it is drawing the line cleanly between systems that fall inside the regulated boundary and systems that do not. What does each GxP domain actually cover? The table below summarises the five practical sub-domains an engineering or quality lead is likely to encounter when scoping a system. Domain Full name Scope Key regulation GMP Good Manufacturing Practice Production, packaging, labelling, storage EU GMP Annex 11, 21 CFR Part 211 GLP Good Laboratory Practice Non-clinical safety studies 21 CFR Part 58, OECD GLP GCP Good Clinical Practice Clinical trials and human subject data ICH E6(R2) GDP Good Distribution Practice Storage and transport of finished products EU GDP Guidelines 2013/C 343/01 GVP Good Pharmacovigilance Practice Adverse event monitoring and reporting EU GVP Modules I–XVI In our experience, a common misconception is that GxP applies uniformly to every system in a pharmaceutical facility. It does not. A meeting-room booking system in a GMP facility is not GxP-relevant. A warehouse management system that tracks temperature-controlled product storage is. The determining factor is whether the system creates, modifies, maintains, or transmits data that affects product quality, patient safety, or data integrity. That distinction — observed across our pharma engagements rather than benchmarked — is what separates proportional compliance from over-scoping. Where does AI software intersect with GxP? AI and machine learning systems in pharma manufacturing trigger GxP requirements when they participate in quality-affecting decisions. A computer vision system performing automated visual inspection of injectable vials is GxP-relevant because its output directly determines whether product reaches patients. A predictive maintenance model forecasting HVAC filter replacement schedules is typically not GxP-relevant unless the HVAC system directly controls a classified manufacturing environment. The boundary is drawn by what the model’s output influences, not by where the model runs. Traditional GxP validation (IQ/OQ/PQ) assumes deterministic software — given the same input, the system produces the same output. Machine learning models do not behave this way. Their outputs change as training data changes, as model weights are updated, and as input distributions shift. This is why the GAMP 5 Second Edition (2022) introduced a risk-based approach that moves away from rigid category-based testing toward continuous monitoring and critical thinking. In practice, an ONNX or TensorRT model serving inspection inference inside a regulated workflow needs runtime checks — input-distribution monitoring, drift detection, output sampling against a ground-truth panel — that a deterministic PLC controller never required. For a deeper treatment of how GAMP categorisation, training-data provenance, and continuous validation fit together, see our explanation of GxP regulations as they apply to AI software in pharma. GxP compliance is a scope decision, not a blanket mandate Three questions determine whether a system falls under GxP: Does the system affect product quality? If a failure or error in the system could lead to a product defect, contamination, or mislabelling, it is GxP-relevant. Does the system generate or manage GxP data? Batch records, analytical results, environmental monitoring data, deviation records, and stability data are all GxP data. Systems that create, modify, or store this data inherit GxP obligations. Does the system support a GxP process? Even if the system itself does not generate data, if it enables or controls a GxP process (for example, a SCADA system controlling a bioreactor), it falls within scope. If the answer to all three is no, the system is not GxP-relevant. Treating non-GxP systems as GxP-relevant wastes validation effort and creates compliance noise that makes real quality issues harder to identify. This is not a hypothetical — across our pharma engagements (observed pattern, not a benchmarked rate) the most expensive scoping errors are systematically in the over-scoping direction, because the under-scoping ones get caught at audit and corrected. How do engineering teams interact with GxP in daily work? For engineering teams building or maintaining systems in pharmaceutical environments, GxP affects three daily activities: development practices, change management, and incident response. None of these are exotic; they map onto how mature software teams already work, but with documentation and authorisation gates that have legal weight. Development practices require that code changes to GxP-regulated systems follow documented procedures. Each change carries a change request describing what will change and why, an impact assessment naming which validated functions could be affected, a test plan, and approval by authorised personnel including quality representation. This does not prohibit modern development practices like continuous integration with Docker-packaged builds and Kubernetes-orchestrated test environments — it requires that the CI pipelines include the documentation and approval steps as first-class artifacts, not afterthoughts bolted on at release time. Change management means deploying changes to production GxP systems requires formal release procedures. Emergency changes (critical bug fixes) have expedited procedures but still require post-deployment documentation and review. The key discipline is that no change reaches production without documented evidence that it was tested, reviewed, and approved. For AI components specifically, this includes the model artefact itself, the training-data snapshot, and the validation report against the acceptance set. Incident response means that when a GxP system fails or produces unexpected results, the incident must be documented, investigated, and resolved through the quality system’s deviation handling process. The investigation determines whether the incident affected product quality or data integrity, what corrective action is needed, and what preventive action will stop it recurring. We train engineering teams on these practices through hands-on workshops that integrate GxP requirements into their existing development workflow rather than treating compliance as a separate activity. The aim is to make compliance a natural part of how the team builds software, not a layer applied afterwards. FAQ What does GxP compliance specifically require when the software is AI/ML rather than deterministic code? The same regulatory obligations apply, but the validation strategy shifts. Deterministic IQ/OQ/PQ assumes identical inputs produce identical outputs. ML models need additional controls: documented training data provenance, model-version control, an acceptance test set with locked ground truth, drift monitoring in production, and a defined retraining-and-revalidation procedure. GAMP 5 Second Edition (2022) frames this as risk-based critical thinking rather than a fixed category. Which GxP rules apply to AI training data, models, and inference outputs? Training data is treated as GxP data if it derives from a GxP process — it inherits ALCOA+ data-integrity requirements and the firm’s electronic-records controls (e.g. 21 CFR Part 11, EU GMP Annex 11). The model is treated as a validated configurable component: version-controlled, change-controlled, and tied to a release record. Inference outputs that drive quality decisions are subject to audit trail and review requirements identical to any other quality-relevant output. How is a GxP-validated AI system kept compliant as the model retrains or drifts? By treating retraining as a controlled change. Each retraining event is a change request with impact assessment against the validated use case, a re-execution of the acceptance test set, comparison against the previous model’s performance on that set, and quality approval before deployment. Drift monitoring in production triggers the retraining decision; it does not bypass the change-control gate. Where is the boundary between GxP and non-GxP usage of AI inside a pharma manufacturing workflow? The boundary is drawn by the three scope questions above: does the system affect product quality, manage GxP data, or support a GxP process. A vision model deciding vial acceptance is GxP. A vision model counting people in a cafeteria is not. A predictive-maintenance model is usually not GxP unless its output directly governs a classified environment or a quality-critical asset. Which GxP roles (system owner, QA, validation lead) own AI-specific risks and how is that documented? The system owner is accountable for the system meeting its intended use and for keeping the validation state current. QA approves the validation strategy, the acceptance criteria, and every change. The validation lead executes and documents the protocols. AI-specific risks — training-data drift, model degradation, edge-case behaviour — are added to the system’s risk assessment and traced through to specific mitigations (monitoring, retraining triggers, fallback procedures) in the validation plan. How do ISPE’s GAMP AI guidance and the ISPE AI maturity model fit into an existing GxP programme? GAMP AI guidance extends the existing GAMP 5 risk-based framework to ML components; it does not replace the firm’s quality system. The AI maturity model is a self-assessment tool that helps the firm see where its AI governance is today and what controls are missing. Both are layered on top of the existing GxP programme — they do not create a parallel regulatory regime.
